couter

KPTIKaryopharm Therapeutics Inc.

Health CareBiotechnology

Karyopharm Therapeutics Inc. (KPTI) sells selinexor, a selective inhibitor of nuclear export, primarily for the treatment of myelofibrosis and certain cancers. The next catalyst is Nov 2, 2026 — Q3 2026 Earnings Release & 2Q27 Guidance, which will test the company’s ability to stabilize cash flow and deliver revenue growth amid persistent losses.

  • KPTI’s revenue grew 0.6% YoY to $150.47M, but net income remains -$159.79M, with free cash flow at -$191.80M TTM.
  • The company has negative shareholders’ equity of -$292.93M and a debt-to-equity ratio of -0.58x.
  • KPTI’s net margin is -106.2% TTM, reflecting heavy R&D and commercialization costs.
Nov 2, 2026 — Q3 2026 Earnings Release & 2Q27 Guidance
Chart by TradingView

The schedule

  • Mon2Nov

    This earnings release will test the company's ability to provide forward-looking guidance and demonstrate progress in its clinical and financial performance.

  • Sun22Nov

    This event will test the company's ability to deliver positive clinical data or regulatory news, which could significantly impact investor sentiment and valuation.

  • Mon1Feb

    This event will test the company's ability to deliver on its strategic vision, including potential partnerships, pipeline advancements, and financial performance.

  • Mon3May
  • Mon2Aug

    This earnings report will test the company's ability to deliver on its long-term financial and strategic goals, particularly in light of its recent clinical and regulatory progress.

Past

  • Mon3Aug

    Actual outcome: Bear · $1.88 at outcome

    KPTI reported an EPS actual of -11.70, matching the estimate, but the stock fell 5.3% from the event date to the outcome date. The guidance highlighted concerns over cash runway and continued negative free cash flow, which overshadowed the earnings beat, leading to a bearish price reaction.

    Q2 2026 earnings and guidance will focus on XPOVIO commercial traction, R&D spend, and cash runway. With Karyopharm trading near its 52-week high at $9.68 despite ongoing losses and negative free cash flow, the bar is high: investors will want evidence that revenue growth can offset burn without an imminent dilutive financing.